Exelixis Stock

Exelixis Goodwill

The Goodwill of Exelixis (EXEL) as of Aug 25, 2026 is 63.68 M USD. In the previous year, Goodwill was 63.68 M USD — a change of 0.00% (lower).

Goodwill

63.68 MUSD

YoY

0.00%

Last updated:

Goodwill of Exelixis is 2026 63.68 M USD. Goodwill of Exelixis was 2025 63.68 M USD. It decreases by 0.00% lower compared to the previous year.

The Exelixis Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2018
63.68 M USD
Jan 1, 2019
63.68 M USD
Jan 1, 2020
63.68 M USD
Jan 1, 2021
63.68 M USD
Jan 1, 2022
63.68 M USD
Jan 1, 2023
63.68 M USD
Jan 1, 2024
63.68 M USD
Jan 1, 2025
63.68 M USD
The Exelixis Goodwill history
YEARGoodwillYoY
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD0.00%
63.68 MUSD
Access this data via the Eulerpool API

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

Goodwill of Exelixis is 63.68 M USD in 2026.

Goodwill of Exelixis changed from 63.68 M USD to 63.68 M USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Exelixis since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Exelixis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Exelixis

All Key Metrics — Exelixis